Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AvaTax in Metastatic Esophagogastric Cancer
NCT00137813Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2004
- Primary completion
- Sep 2006
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and docetaxel in esophageal cancer and gastric cancer (GC), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Overall Response Rate at 3 years and Safety and Tolerability at 3 years. Started Aug 2004; status: completed.
02
Drugs
bevacizumabdocetaxel
03
Conditions
esophageal cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT00137813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00137813.